May 12 (UPI) -- U.S. health officials are advising patients using the drug Ixchiq to hold off while authorities seek newer information on vaccine results in the global fight against chikungunya. The pause for U.S. patients was initiated Friday by the FDA and CDC while the two federal agencies investigate "postmarketing reports of serious adverse events, including neurologic and cardiac events, in individuals who have received the vaccine" Ixchiq, otherwise known as live "Chikungunya Vaccine,"